Amino.Desk

PT-141 (bremelanotide, Vyleesi)

Updated Nov 17, 2026 · Clinical review: pending

PT-141 is the research name for bremelanotide, which the FDA approved in 2019 as Vyleesi. The approval is narrow: low sexual desire in premenopausal women. It is not approved for men, for postmenopausal women, or to improve sexual performance.

Want PT-141 from a licensed pharmacy instead of a research vial? HealthRX prescribes it online and ships overnight.

See today's price at HealthRX →

Affiliate link. Compounded medications are not FDA-approved. More below.

What it is

Bremelanotide activates melanocortin receptors in the brain, the same receptor family that Melanotan II acts on. It was developed from that line of research, which is why it shares some of the same side effects, including skin darkening.

What the evidence shows

Approval rested on two identical Phase 3 trials, called RECONNECT, in about 1,250 premenopausal women with acquired low sexual desire. Over 24 weeks, bremelanotide improved desire scores and reduced distress about low desire compared with placebo, and a 52-week open-label extension found the improvement held.

The effect was measured on questionnaires. An editorial published alongside the trials noted that the studies did not show an increase in the number of sexual events.

Dosing on the label

The vials of "PT-141" sold online are the same molecule in unregulated powder form. Their purity and content are unverified, and nothing about men or daily use has been established by the trials above.

Side effects and warnings

Affiliate links

Get PT-141 prescribed online

Skip the research-vial gamble. HealthRX connects you with a licensed provider, and a US-licensed pharmacy fills the prescription and ships it to your door.

See today's price at HealthRX →

Affiliate links: Amino Desk earns a commission if you sign up, at no extra cost to you. Compounded medications are not FDA-approved, and a licensed provider decides whether one is right for you. How our partners score on our checks. This is a compounded version of bremelanotide, not the Vyleesi autoinjector.

Common questions

What is PT-141 approved for?

As Vyleesi, it is FDA-approved for low sexual desire in premenopausal women. It is not approved for men or for postmenopausal women.

What is the Vyleesi dose?

The label dose is 1.75 mg injected under the skin as needed, at least 45 minutes before expected sexual activity. The limits are one dose in 24 hours and 8 doses a month.

What are the side effects of PT-141?

Nausea is the most common, along with flushing and headache. Each dose raises blood pressure for several hours, and patches of darker skin appeared in 1% of trial patients.

Added in the latest update. These answers summarize the sections above; sources are listed below.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy